Treatment failure Need to intensify therapy/ED or hospital admission · exacerbations of COPD
Systemic corticosteroid leads to lower treatment failure Need to intensify therapy/ED or hospital admission compared with placebo (high certainty).
1 finding from 1 review
Mortality after discharge (1‐3 months) · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in mortality after discharge (1‐3 months) compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Arterial blood gas tension: PaO2 after 3 months mmHg · exacerbations of COPD
1 finding from 1 review
Relapse Treatment for AE of COPD or hospital re‐admission · exacerbations of COPD
Systemic corticosteroid showed no clear difference in relapse Treatment for AE of COPD or hospital re‐admission compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · exacerbations of COPD
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review
Adverse drug reactions · exacerbations of COPD
Systemic corticosteroid leads to higher adverse drug effect compared with placebo (high certainty).
1 finding from 1 review
Hyperglycaemia · exacerbations of COPD
Systemic corticosteroid leads to higher hyperglycaemia compared with placebo (high certainty).
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in treatment failure Need to intensify therapy compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Relapse Hospital readmission for COPD · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in relapse Hospital readmission for COPD compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review
Frequency and duration of exacerbations · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Health‐related quality of life · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Symptoms sputum colour Scale used not reported · people with bronchiectasis
RhDNase showed no clear difference in symptoms sputum colour Scale used not reported compared with placebo (low certainty).
1 finding from 1 review
Deaths · people with bronchiectasis
RhDNase showed no clear difference in deaths compared with placebo (low certainty).
1 finding from 1 review
Lung function: FEV1 mL (percentage change from baseline) · people with bronchiectasis
RhDNase showed no clear difference in lung function % change FEV1 compared with placebo (low certainty).
1 finding from 1 review
Frequency and duration of exacerbations · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review